The activation of Vγ9Vδ2 T cells has emerged as a promising modality in cancer immunotherapy. Phosphate and phosphonate prodrugs of Vγ9Vδ2 T cell phosphoantigens have been developed as potent activators of Vγ9Vδ2 T cells that are capable of effectively facilitating lysis of a range of cancer cells in vitro. In this wor...
M. Sharif, C. M. A. Pinna, K. Rakhimova et al.· ACS Pharmacology & Translati...· 0 citations
Background Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, and emerging T cell engager (TCE) immunotherapies require predictive preclinical models that capture patient-specific tumour biology and tumour-immune interactions. Although patient-derived organoid (PDO)-immune co-culture systems s...
C. M. A. Pinna, K. Rakhimova, Jing Zhang et al.· bioRxiv· 0 citations
Data show that IGF2BP3 is expressed consistently in PDAC, plays a dominant role in regulation of RNA splicing and modification, and supports cancer stem cell proliferation and survival, and represents an important therapeutic target in this tumour of unmet need.
Sandra Margielewska-Davies, W. Croft, H. Pearce et al.· Oncogene· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.